Last reviewed · How we verify
NCT07222280
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
NA trial testing Quest AD-Detect blood test in Alzheimer Dementia in 30 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Covenant Health, US |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 10 June 2025 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2026 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- Quest AD-Detect blood test
Conditions studied
- Alzheimer Dementia — all drugs for Alzheimer Dementia →
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Delirium Confusional State — all drugs for Delirium Confusional State →
- Encephalopathy — all drugs for Encephalopathy →
Sponsor
Covenant Health, US
Who can join
Adults 60 to 90, any sex, with Alzheimer Dementia or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07222280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Dementia
Currently open trials in the same condition.
- NCT07140601 — Environmental Pollutants and Neurological Disorders · recruiting
- NCT04838301 — Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease · Phase 2 · recruiting
- NCT03926520 — Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) · NA · recruiting
- NCT04289402 — Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease · NA · active not recruiting
- NCT04055376 — Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07222280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Covenant Health, US
- Last refreshed: 29 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07222280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing